Metabolism of Triglyceride-Rich Lipoproteins.
Apolipoprotein B
Chylomicrons
Hypertriglyceridemia
Metabolism
Therapies
Triglyceride-rich lipoproteins (TRL)
Very low density lipoproteins (VLDL)
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
23
10
2021
medline:
3
2
2022
entrez:
22
10
2021
Statut:
ppublish
Résumé
Triglycerides are critical lipids as they provide an energy source that is both compact and efficient. Due to its hydrophobic nature triglyceride molecules can pack together densely and so be stored in adipose tissue. To be transported in the aqueous medium of plasma, triglycerides have to be incorporated into lipoprotein particles along with other components such as cholesterol, phospholipid and associated structural and regulatory apolipoproteins. Here we discuss the physiology of normal triglyceride metabolism, and how impaired metabolism induces hypertriglyceridemia and its pathogenic consequences including atherosclerosis. We also discuss established and novel therapies to reduce triglyceride-rich lipoproteins.
Identifiants
pubmed: 34676434
doi: 10.1007/164_2021_520
doi:
Substances chimiques
Apolipoproteins
0
Lipoproteins
0
Lipoproteins, VLDL
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-156Informations de copyright
© 2021. The Author(s).
Références
Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Summerbell CD, Worthington HV, Song F, Hooper L (2020) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 3:CD003177
pubmed: 32114706
Adiels M, Packard C, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Taskinen MR, Boren J (2005) A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 46(1):58–67
pubmed: 15489544
Adiels M, Olofsson SO, Taskinen MR, Boren J (2006a) Diabetic dyslipidaemia. Curr Opin Lipidol 17(3):238–246
pubmed: 16680028
Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J (2006b) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49(4):755–765
pubmed: 16463046
Adiels M, Matikainen N, Westerbacka J, Soderlund S, Larsson T, Olofsson SO, Boren J, Taskinen MR (2012) Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 222(1):222–228
pubmed: 22365426
Adiels M, Taskinen MR, Bjornson E, Andersson L, Matikainen N, Soderlund S, Kahri J, Hakkarainen A, Lundbom N, Sihlbom C, Thorsell A, Zhou H, Pietilainen KH, Packard C, Boren J (2019) Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. Diabetes Obes Metab 21(8):1861–1870
pubmed: 30972934
Aguilar-Salinas CA, Barrett PH, Parhofer KG, Young SG, Tessereau D, Bateman J, Quinn C, Schonfeld G (1995) Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. Arterioscler Thromb Vasc Biol 15(1):71–80
pubmed: 7749818
Anant S, Davidson NO (2001) Molecular mechanisms of apolipoprotein B mRNA editing. Curr Opin Lipidol 12(2):159–165
pubmed: 11264987
Asp L, Magnusson B, Rutberg M, Li L, Boren J, Olofsson SO (2005) Role of ADP ribosylation factor 1 in the assembly and secretion of ApoB-100-containing lipoproteins. Arterioscler Thromb Vasc Biol 25(3):566–570
pubmed: 15618550
Austin MA, King M-C, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495–506
pubmed: 2372896
Barrows BR, Parks EJ (2006) Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 91(4):1446–1452
pubmed: 16449340
Bauer RC, Khetarpal SA, Hand NJ, Rader DJ (2016) Therapeutic targets of triglyceride metabolism as informed by human genetics. Trends Mol Med 22(4):328–340
pubmed: 26988439
Bays HE, Tighe AP, Sadovsky R, Davidson MH (2008) Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 6(3):391–409
pubmed: 18327998
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, Investigators R-I (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11–22
pubmed: 30415628
Bjornson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Soderlund S, Kahri J, Hakkarainen A, Lundbom N, Lundbom J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Boren J (2019a) Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. J Intern Med 288(4):422–438
Bjornson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Soderlund S, Kahri J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Boren J (2019b) Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics. J Intern Med 285(5):562–577
pubmed: 30779243
pmcid: 6849847
Boren J, Graham L, Wettesten M, Scott J, White A, Olofsson SO (1992) The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins. J Biol Chem 267(14):9858–9867
pubmed: 1315773
Boren J, Matikainen N, Adiels M, Taskinen MR (2014) Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta 431:131–142
pubmed: 24508990
Borén J, Watts GF, Adiels M, Söderlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Vergès B, Barrett PHR, Taskinen M (2015) Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity. Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol 35(10):2218–2224
pubmed: 26315407
Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41(24):2313–2330
pubmed: 32052833
pmcid: 7308544
Bostrom K, Boren J, Wettesten M, Sjoberg A, Bondjers G, Wiklund O, Carlsson P, Olofsson SO (1988) Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. J Biol Chem 263(9):4434–4442
pubmed: 3346254
Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114(2):147–152
pubmed: 15254578
pmcid: 15254578
Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106(10):1221–1228
pubmed: 11086023
pmcid: 381440
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32(11):1345–1361
pubmed: 21531743
pmcid: 3105250
Chavez-Jauregui RN, Mattes RD, Parks EJ (2010) Dynamics of fat absorption and effect of sham feeding on postprandial lipema. Gastroenterology 139(5):1538–1548
pubmed: 20493191
Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM, Li W, Dou A, Zhang R, Davies BSJ (2017) ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab 6(10):1137–1149
pubmed: 29031715
pmcid: 5641604
Christopoulou E, Elisaf M, Filippatos T (2019) Effects of angiopoietin-like 3 on triglyceride regulation, glucose homeostasis, and diabetes. Dis Markers 2019:6578327
pubmed: 30944669
pmcid: 6421734
Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ (1993) Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 34(12):2033–2040
pubmed: 8301224
Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F, Kastelein JJ, Peterfy M, Nieuwdorp M (2010) The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 211(1):1–8
pubmed: 20117784
Dallinga-Thie GM, Kroon J, Boren J, Chapman MJ (2016) Triglyceride-rich lipoproteins and remnants: targets for therapy? Curr Cardiol Rep 18(7):67
pubmed: 27216847
pmcid: 4877422
Davidson NO, Shelness GS (2000) APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 20:169–193
pubmed: 10940331
Davies BSJ (2018) Can targeting ANGPTL proteins improve glucose tolerance? Diabetologia 61(6):1277–1281
pubmed: 29619530
pmcid: 5940535
Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, Hunt C, Van Hout CV, Habegger L, Buckler D, Lai KM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Ledbetter DH, Penn J, Lopez A, Borecki IB, Overton JD, Reid JG, Carey DJ, Murphy AJ, Yancopoulos GD, Baras A, Gromada J, Shuldiner AR (2016) Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med 374(12):1123–1133
pubmed: 26933753
pmcid: 4900689
Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjaerg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A (2017) Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 377(3):211–221
pubmed: 28538136
pmcid: 5800308
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM (2016) Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care 39(8):1408–1415
pubmed: 27271183
Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkila K, Hypponen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikainen LP, Magnusson PK, Mangino M, Mihailov E, Montasser ME, Muller-Nurasyid M, Nolte IM, O’Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney AS, Doring A, Elliott P, Epstein SE, Eyjolfsson GI, Gigante B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimaki T, Lin SY, Lindstrom J, Loos RJ, Mach F, WL MA, Meisinger C, Mitchell BD, Muller G, Nagaraja R, Narisu N, Nieminen TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stancakova A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YD, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrieres J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Jarvelin MR, Jula A, Kahonen M, Kaprio J, Kesaniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, Marz W, MI MC, CA MK, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, Njolstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PE, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolffenbuttel BH, Altshuler D, Ordovas JM, Boerwinkle E, Palmer CN, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Mohlke KL, Ingelsson E, Abecasis GR, Daly MJ, Neale BM, Kathiresan S (2013) Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 45(11):1345–1352
pubmed: 24097064
pmcid: 3904346
Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL, NES P, Girelli D, Martinelli N, Farlow DN, MA DP, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, Siscovick DS, McPherson R, Tybjaerg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyaev SR, O’Donnell CJ, Altshuler D, Gabriel S, Kathiresan S (2015) Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518(7537):102–106
pubmed: 25487149
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343–1351
pubmed: 15864352
pmcid: 15864352
Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH (2015) Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis 14:98
pubmed: 26328624
pmcid: 4557761
Edvardsson U, Bergstrom M, Alexandersson M, Bamberg K, Ljung B, Dahllof B (1999) Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res 40(7):1177–1184
pubmed: 10393202
Elias N, Patterson BW, Schonfeld G (1999) Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 19(11):2714–2721
pubmed: 10559016
Farquhar JW, Gross RC, Wagner RM, Reaven GM (1965) Validation of an incompletely coupled two-compartment nonrecycling catenary model for turnover of liver and plasma triglyceride in man. J Lipid Res 6:119–134
pubmed: 14280459
Fielding BA, Reid G, Grady M, Humphreys SM, Evans K, Frayn KN (2000) Ethanol with a mixed meal increases postprandial triacylglycerol but decreases postprandial non-esterified fatty acid concentrations. Br J Nutr 83(6):597–604
pubmed: 10911767
Gardner CD, Fortmann SP, Krauss RM (1996) Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875–881
pubmed: 8782636
Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL (2014) Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371(23):2200–2206
pubmed: 25470695
Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373(5):438–447
pubmed: 26222559
Gaudet D, Drouin-Chartier JP, Couture P (2017a) Lipid metabolism and emerging targets for lipid-lowering therapy. Can J Cardiol 33(7):872–882
pubmed: 28365054
Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK (2017b) ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 377(3):296–297
pubmed: 28723334
Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J (1995) Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 36(1):158–171
pubmed: 7706941
Georgieva AM, van Greevenbroek MM, Krauss RM, Brouwers MC, Vermeulen VM, Robertus-Teunissen MG, van der Kallen CJ, de Bruin TW (2004) Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 24(4):744–749
pubmed: 14751815
Gibbons GF, Islam K, Pease RJ (2000) Mobilisation of triacylglycerol stores. Biochim Biophys Acta 1483(1):37–57
pubmed: 10601694
Ginsberg HN, Brown WV (2011) Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol 31(3):471–473
pubmed: 21325666
Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV, Apolipoprotein B (1986) Metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78(5):1287–1295
pubmed: 3095375
pmcid: 423815
Goldberg IJ (1996) Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37(4):693–707
pubmed: 8732771
Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD (2016) ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest 126(8):2855–2866
pubmed: 27400128
pmcid: 4966320
Gouni-Berthold I (2017) The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atheroscler Suppl 30:19–27
pubmed: 29096837
Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112(11):1479–1490
pubmed: 23542898
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S (2017) Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 377(3):222–232
pubmed: 28538111
Gusarova V, Brodsky JL, Fisher EA (2003) Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J Biol Chem 278(48):48051–48058
pubmed: 12960170
Haller JF, Mintah IJ, Shihanian LM, Stevis P, Buckler D, Alexa-Braun CA, Kleiner S, Banfi S, Cohen JC, Hobbs HH, Yancopoulos GD, Murphy AJ, Gusarova V, Gromada J (2017) ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res 58(6):1166–1173
pubmed: 28413163
pmcid: 5454515
Havel RJ (1961) Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism 10:1031–1034
pubmed: 13905468
Huff MW, Hegele RA (2013) Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res 112(11):1405–1408
pubmed: 23704213
Hussain MM, Fatma S, Pan X, Iqbal J (2005) Intestinal lipoprotein assembly. Curr Opin Lipidol 16(3):281–285
pubmed: 15891388
James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ et al (1989) Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res 30(2):159–169
pubmed: 2715722
Julve J, Martin-Campos JM, Escola-Gil JC, Blanco-Vaca F (2016) Chylomicrons: advances in biology, pathology, laboratory testing, and therapeutics. Clin Chim Acta 455:134–148
pubmed: 26868089
Karpe F, Bell M, Bjorkegren J, Hamsten A (1995) Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 15(2):199–207
pubmed: 7749826
Keech AC, Jenkins AJ (2017) Triglyceride-lowering trials. Curr Opin Lipidol 28(6):477–487
pubmed: 28957862
Kersten S (2014) Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 1841(7):919–933
pubmed: 24721265
Kersten S (2017) Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol 13(12):731–739
pubmed: 28984319
Khan NA, Besnard P (2009) Oro-sensory perception of dietary lipids: new insights into the fat taste transduction. Biochim Biophys Acta 1791(3):149–155
pubmed: 19367762
Koo SH, Dutcher AK, Towle HC (2001) Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem 276(12):9437–9445
pubmed: 11112788
Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95(1):69–75
pubmed: 8994419
Lambert JE, Parks EJ (2012) Postprandial metabolism of meal triglyceride in humans. Biochim Biophys Acta 1821(5):721–726
pubmed: 22281699
pmcid: 3588585
Larsson M, Vorrsjo E, Talmud P, Lookene A, Olivecrona G (2013) Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem 288(47):33997–34008
pubmed: 24121499
pmcid: 3837139
Laufs U, Parhofer KG, Ginsberg HN, Hegele RA (2020) Clinical review on triglycerides. Eur Heart J 41(1):99–109c
pubmed: 31764986
Lee J, Hegele RA (2014) Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis 37(3):333–339
pubmed: 24288038
Li J, Li L, Guo D, Li S, Zeng Y, Liu C, Fu R, Huang M, Xie W (2020) Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation. Clin Chim Acta 503:19–34
pubmed: 31923423
Lichtenstein AH, Hachey DL, Millar JS, Jenner JL, Booth L, Ordovas J, Schaefer EJ (1992) Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-2H3]leucine. J Lipid Res 33(6):907–914
pubmed: 1512514
Linton MF, Farese RV Jr, Young SG (1993) Familial hypobetalipoproteinemia. J Lipid Res 34(4):521–541
pubmed: 8496659
Luo M, Peng D (2018) ANGPTL8: an important regulator in metabolic disorders. Front Endocrinol (Lausanne) 9:169
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188
pubmed: 31504418
Mahley RW, Huang Y (2007) Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest 117(1):94–98
pubmed: 17200713
pmcid: 1716223
Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M (2011) Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 5(6):483–492
pubmed: 22108152
Marais AD (2019) Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology 51(2):165–176
pubmed: 30598326
Matikainen N, Soderlund S, Bjornson E, Pietilainen K, Hakkarainen A, Lundbom N, Taskinen MR, Boren J (2019) Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab 21(1):84–94
pubmed: 30073766
Mattes RD (2002) Oral fat exposure increases the first phase triacylglycerol concentration due to release of stored lipid in humans. J Nutr 132(12):3656–3662
pubmed: 12468603
Mattes RD (2009) Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans. Am J Physiol Gastrointest Liver Physiol 296(2):G365–G371
pubmed: 19074638
Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM (2010) Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 30(2):239–245
pubmed: 19910636
Minicocci I, Santini S, Cantisani V, Stitziel N, Kathiresan S, Arroyo JA, Marti G, Pisciotta L, Noto D, Cefalu AB, Maranghi M, Labbadia G, Pigna G, Pannozzo F, Ceci F, Ciociola E, Bertolini S, Calandra S, Tarugi P, Averna M, Arca M (2013) Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res 54(12):3481–3490
pubmed: 24058201
pmcid: 3826694
Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM (2016) The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol 10(6):1442–1451.e4
pubmed: 27919362
Myocardial Infarction Genetics Investigators CAEC, Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, Konig IR, Weeke PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kanoni S, Kruppa J, Mahajan A, Scott RA, Willenberg C, Braund PS, van Capelleveen JC, Doney AS, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer CM, El-Mokhtari NE, Franke A, Gottesman O, Heilmann S, Hengstenberg C, Hoffman P, Holmen OL, Hveem K, Jansson JH, Jockel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, MI MC, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Muller-Nurasyid M, Nikpay M, Olivieri O, Lemieux Perreault LP, AlQarawi A, Robertson NR, Akinsanya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Strauch K, Varga TV, Waldenberger M, Zeng L, Kraja AT, Liu C, Ehret GB, Newton-Cheh C, Chasman DI, Chowdhury R, Ferrario M, Ford I, Jukema JW, Kee F, Kuulasmaa K, Nordestgaard BG, Perola M, Saleheen D, Sattar N, Surendran P, Tregouet D, Young R, Howson JM, Butterworth AS, Danesh J, Ardissino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, Kastrati A, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melander M, Melander O, Metspalu A, Palmer CN, Peters A, Rader D, Reilly MP, Loos RJ, Reiner AP, Roden DM, Tardif JC, Thompson JR, Wareham NJ, Watkins H, Willer CJ, Kathiresan S, Deloukas P, Samani NJ, Schunkert H (2016) Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med 374(12):1134–1144
Nakajima K, Tokita Y, Tanaka A, Takahashi S (2019) The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins. Clin Chim Acta 495:382–393
pubmed: 31078566
Norata GD, Tsimikas S, Pirillo A, Catapano AL (2015) Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci 36(10):675–687
pubmed: 26435212
Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635
pubmed: 25131982
Olofsson SO, Boren J (2005) Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 258(5):395–410
pubmed: 16238675
Olofsson SO, Stillemark-Billton P, Asp L (2000) Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med 10(8):338–345
pubmed: 11369260
Ooi EM, Watts GF, Chan DC, Chen MM, Nestel PJ, Sviridov D, Barrett PH (2008) Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care 31(8):1656–1661
pubmed: 18509206
pmcid: 2494658
Ooi EM, Russell BS, Olson E, Sun SZ, Diffenderfer MR, Lichtenstein AH, Keilson L, Barrett PH, Schaefer EJ, Sprecher DL (2012) Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations. Arterioscler Thromb Vasc Biol 32(2):459–466
pubmed: 22095987
Packard CJ (2003) Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31(Pt 5):1066–1069
pubmed: 14505481
Paquette M, Dufour R, Hegele RA, Baass A (2016) A tale of 2 cousins: an atypical and a typical case of abetalipoproteinemia. J Clin Lipidol 10(4):1030–1034
pubmed: 27578136
Parhofer KG, Barrett PH, Aguilar-Salinas CA, Schonfeld G (1996) Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. J Lipid Res 37(4):844–852
pubmed: 8732784
Parks EJ, Hellerstein MK (2006) Thematic review series: patient-oriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res 47(8):1651–1660
pubmed: 16741290
Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK (1999) Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest 104(8):1087–1096
pubmed: 10525047
pmcid: 408572
Poulsen MK, Nellemann B, Stodkilde-Jorgensen H, Pedersen SB, Gronbaek H, Nielsen S (2016) Impaired insulin suppression of VLDL-triglyceride kinetics in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 101(4):1637–1646
pubmed: 26829441
Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM (2018) Rationale and design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J 206:80–93
pubmed: 30342298
Prinsen BH, Romijn JA, Bisschop PH, de Barse MM, Barrett PH, Ackermans M, Berger R, Rabelink TJ, de Sain-van der Velden MG (2003) Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res 44(7):1341–1348
pubmed: 12700338
Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R (2019) Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort. Eur Heart J 40(33):2813–2824
pubmed: 31236578
pmcid: 6735871
Robertson MD, Henderson RA, Vist GE, Rumsey RD (2002) Extended effects of evening meal carbohydrate-to-fat ratio on fasting and postprandial substrate metabolism. Am J Clin Nutr 75(3):505–510
pubmed: 11864856
Robertson MD, Parkes M, Warren BF, Ferguson DJ, Jackson KG, Jewell DP, Frayn KN (2003) Mobilisation of enterocyte fat stores by oral glucose in humans. Gut 52(6):834–839
pubmed: 12740339
pmcid: 1773679
Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC (2009) Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 119(1):70–79
pubmed: 19075393
Rustaeus S, Stillemark P, Lindberg K, Gordon D, Olofsson SO (1998) The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J Biol Chem 273(9):5196–5203
pubmed: 9478974
Sacks FM (2015) The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol 26(1):56–63
pubmed: 25551803
pmcid: 4371603
Sacks FM, Campos H (2003) Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 88(10):4525–4532
pubmed: 14557416
Salter AM, Wiggins D, Sessions VA, Gibbons GF (1998) The intracellular triacylglycerol/fatty acid cycle: a comparison of its activity in hepatocytes which secrete exclusively apolipoprotein (apo) B100 very-low-density lipoprotein (VLDL) and in those which secrete predominantly apoB48 VLDL. Biochem J 332(Pt 3):667–672
pubmed: 9620868
pmcid: 1219526
Sandesara PB, Virani SS, Fazio S, Shapiro MD (2019) The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 40(2):537–557
pubmed: 30312399
Schneeman BO, Kotite L, Todd KM, Havel RJ (1993) Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A 90(5):2069–2073
pubmed: 8446630
pmcid: 46022
Segrest JP, Jones MK, De Loof H, Dashti N (2001) Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42(9):1346–1367
pubmed: 11518754
Shimomura I, Bashmakov Y, Horton JD (1999) Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274(42):30028–30032
pubmed: 10514488
Stillemark P, Boren J, Andersson M, Larsson T, Rustaeus S, Karlsson KA, Olofsson SO (2000) The assembly and secretion of apolipoprotein B-48-containing very low density lipoproteins in McA-RH7777 cells. J Biol Chem 275(14):10506–10513
pubmed: 10744742
Stillemark-Billton P, Beck C, Boren J, Olofsson SO (2005) Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J Lipid Res 46(1):104–114
pubmed: 15520448
Tamura S, Shimomura I (2005) Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 115(5):1139–1142
pubmed: 15864343
pmcid: 1087181
Tanoli T, Yue P, Yablonskiy D, Schonfeld G (2004) Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res 45(5):941–947
pubmed: 14967820
Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46(6):733–749
pubmed: 12774165
Taskinen MR, Boren J (2015) New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239(2):483–495
pubmed: 25706066
Taskinen MR, Adiels M, Westerbacka J, Soderlund S, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Olofsson SO, Orho-Melander M, Boren J (2011) Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 31(9):2144–2150
pubmed: 21778423
Tsimikas S (2018) RNA-targeted therapeutics for lipid disorders. Curr Opin Lipidol 29(6):459–466
pubmed: 30234555
Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR (2002) Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 18(6):484–490
pubmed: 12469362
Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107(13):1733–1737
pubmed: 12665498
Vatner DF, Goedeke L, Camporez JG, Lyu K, Nasiri AR, Zhang D, Bhanot S, Murray SF, Still CD, Gerhard GS, Shulman GI, Samuel VT (2018) Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. Diabetologia 61(6):1435–1446
pubmed: 29497783
pmcid: 5940564
Verges B (2005) New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31(5):429–439
pubmed: 16357786
Wang AB, Liu DP, Liang CC (2003) Regulation of human apolipoprotein B gene expression at multiple levels. Exp Cell Res 290(1):1–12
pubmed: 14516783
Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH (2015a) Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res 56(7):1296–1307
pubmed: 25954050
pmcid: 4479334
Wang Y, McNutt MC, Banfi S, Levin MG, Holland WL, Gusarova V, Gromada J, Cohen JC, Hobbs HH (2015b) Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl Acad Sci U S A 112(37):11630–11635
pubmed: 26305978
pmcid: 4577179
Welty FK (2014) Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 25(3):161–168
pubmed: 24751931
pmcid: 4465983
Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Ordovas JM, Schaefer EJ (1997) Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler Thromb Vasc Biol 17(5):881–888
pubmed: 9157951
Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ (1999) Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 19(12):2966–2974
pubmed: 10591677
Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, Fisher RM, Yki-Jarvinen H (2007) Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56(11):2759–2765
pubmed: 17704301
Wiggins D, Gibbons GF (1992) The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem J 284:457–462
pubmed: 1599431
pmcid: 1132660
Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O’Dea L, Bruckert E (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 381(6):531–542
pubmed: 31390500
Xiao C, Stahel P, Lewis GF (2019) Regulation of chylomicron secretion: focus on post-assembly mechanisms. Cell Mol Gastroenterol Hepatol 7(3):487–501
pubmed: 30819663
Xu YX, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A, Deik A, Trindade K, Wang X, Musunuru K, Clish CB, Cowan C, Fizgerald K, Rader D, Kathiresan S (2018) Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis 268:196–206
pubmed: 29183623
Yao Z (2012) Human apolipoprotein C-III – a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets 12(2):133–140
pubmed: 23030451
Zhang R (2012) Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 424(4):786–792
pubmed: 22809513
Zheng C, Khoo C, Ikewaki K, Sacks FM (2007) Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 48(5):1190–1203
pubmed: 17314277
Zheng C, Khoo C, Furtado J, Sacks FM (2010) Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121(15):1722–1734
pubmed: 20368524
pmcid: 3153990